Open AccessTreatment of patients with systemic lupus erythematosus without glucocorticoids – myth or reality?
Author(s) -
S. Soloviev,
A. Mesnyankina,
Н. Ю. Никишина,
Е. А. Асеева,
А. М. Лила
Publication year - 2022
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2022-1-77-83
Subject(s) - belimumab , rituximab , medicine , lupus erythematosus , systemic lupus erythematosus , glucocorticoid , disease , immunology , dermatology , antibody , b cell activating factor , b cell
Glucocorticoids (GC) currently remain one of the most important components of the treatment of systemic lupus erythematosus (SLE). However, prolonged use of GC inevitably leads to the development of irreversible organ damage. It has been proven that the use of biological diseasemodifying antirheumatic drugs that block key pathogenetic pathways of SLE has an advantage in patients with high disease activity and dependence on the use of medium and high doses of GC.Three clinical cases are presented in which patients with active SLE were treated with rituximab and belimumab without the use of oral GC.